Eli Lilly & Co. vs Novartis AG
LLY vs NVS — side-by-side comparison from reported financials. LLY leads 9, NVS leads 2 of 11 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Novartis AG
NVS · Healthcare
$143.75+0.45%Solid
| Metric | LLY | NVS |
|---|---|---|
| Price | $1 177.20 | $143.75 |
| Market cap | $1.05T | $273B |
| Revenue (TTM) | $79.7B | $56.7B |
| Revenue growth | +31.7% | +9.1% |
| Net margin | 33.5% | 24.7% |
| Free cash flow | $18.2B | $16.8B |
| Net cash (debt) | ($35.2B) | ($41.4B) |
| 1-year price return | +37.6% | +9.7% |
| P/E | 41.6 | 20.3 |
| P/E vs own history (cheap-side %) | 88% | 46% |
| Dividend yield | 0.52% | 3.49% |
| Return on equity | 93% | 30% |
| Altman Z-score | 7.10 | 3.50 |
| CV checks passed | 11 of 11 | 11 of 11 |
| Employees | 50,000 | 75,267 |
Full résumé-style profiles: LLY CV · NVS CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.